Neisseria meningitis carrier

Updated: July 12, 2024

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

rifampin

600mg every 12 hours for two days

meningococcal A C Y and W-135 diphtheria conjugate vaccine

0.5 mL single dose is recommended, and immunization, which is to be carried out, is by only intramuscular (IM) injection

Dose Adjustments

No specific dose adjustments are provided for renal and hepatic impairment patients

sulfisoxazole

Oral administration of 2 g 4 times a day, which is continued for 14 days approximately depending on the severity and nature of the infection
The usual adult dose required for treating this infection is 2 g of oral administration four times daily for 14 days

Dose Adjustments

Not Available

rifampin

<1 month:10mg/kg orally every 12 hours for two days
>1 month: 20mg/kg orally every 12 hours for two days

rifampin

<1 month:10mg/kg orally every 12 hours for two days
>1 month: 20mg/kg orally every 12 hours for two days

meningococcal A C Y and W-135 diphtheria conjugate vaccine

CDC recommends the 0.5 mL IM first dose at 11 years or 12 years, whereas the booster dose of 0.5 mL can be given after four years, that is, at 16 years of age
Two vial presentations can be started at two months, a 4-dose series and equal divided months of 2, 4, and 6, and after a month gap that is at 12 months or two dose series with a second dose administered in the second year after the first dose, which is after three months
A booster dose of 0.5 mL is after 15 years for individuals who are still at risk of contracting meningococcal disease after the first primary dose

Future Trends